Ponatinib抑制野生型和T315I突变型BCR-ABL1激酶的分子模拟

doi:10.16085/j.issn.1000-6613.2017-0891

化工进展 ›› 2018, Vol. 37 ›› Issue (02): 702-707.DOI: 10.16085/j.issn.1000-6613.2017-0891

Ponatinib抑制野生型和T315I突变型BCR-ABL1激酶的分子模拟

陈清, 王坚毅

广西大学化学化工学院, 广西南宁 530004

收稿日期:2017-05-15 修回日期:2017-06-01 出版日期:2018-02-05 发布日期:2018-02-05
通讯作者: 王坚毅,教授,博士生导师,研究方向为分子模拟与药物设计。
作者简介:陈清(1990-),女,硕士研究生。E-mail:13557012644@163.com。
基金资助:
国家自然科学基金项目（21262004）。

Inhibition of Ponatinib on wild-type and T315I mutant BCR-ABL1 kinase based on molecular simulation

CHEN Qing, WANG Jianyi

School of Chemistry and Chemical Engineering, Guangxi University, Nanning 530004, Guangxi, China

Received:2017-05-15 Revised:2017-06-01 Online:2018-02-05 Published:2018-02-05

摘要/Abstract

摘要： 药物普纳替尼（Ponatinib）对野生型和T315I突变型BCR-ABL1激酶均有较强抑制作用，然而其抑制机理仍然未知。为了更好地了解Ponatinib与BCR-ABL1激酶的作用机理，本文首先运用分子动力学模拟方法研究Ponatinib对BCR-ABL1激酶构象变化的影响，然后采用MM-PBSA方法计算复合物的结合自由能。结果表明：Ponatinib诱导野生型BCR-ABL1激酶P-loop和铰链区相互靠近，导致野生型激酶结合口袋关闭，有利于激酶与药物结合；而Ponatinib诱导T315I突变型BCR-ABL1激酶P-loop和铰链区相互远离，导致T315I突变型激酶结合口袋打开，对激酶与药物结合不利；Ponatinib与野生型以及T315I突变型BCR-ABL1激酶的结合自由能分别为-58.57 kcal/mol和-43.54kcal/mol，Ponatinib对野生型BCR-ABL1激酶的抑制能力明显强于T315I突变体，与文献报道的实验抑制活性结果一致。研究结果对认识靶点蛋白和抑制剂分子机制以及设计新药有重要意义。

关键词: 分子模拟, 酶, T315I突变, 普纳替尼, 动力学理论, 活性

Abstract: The drug Ponatinib had a strong inhibitory effect on wild-type and T315I mutant BCR-ABL1 kinase, but its inhibition mechanism was still unknown. To have a better understanding of the interaction mechanism between Ponatinib and BCR-ABL1 kinase, the effect of Ponatinib on the conformational changes of BCR-ABL1 kinase was studied by molecular dynamics simulation at first, and then the binding free energy of complex was calculated by the MM-PBSA method. The results indicated that the P-loop and hinge region of wild-type BCR-ABL1 kinase approached each other induced by Ponatinib, leading to the closure of the binding pocket of wild-type BCR-ABL1 kinase, which would be favorable to the binding of drug. In contrast, the P-loop and hinge region of T315I mutant BCR-ABL1 kinase move far away from each other induced by Ponatinib, resulting in the opening of the binding pocket of T315I mutant BCR-ABL1 kinase, which was no advantage for kinase binding with drug. The binding free energy of Ponatinib bound to wild-type and T315I mutant BCR-ABL1 kinase were -58.57kcal/mol and -43.54kcal/mol, respectively. The results showed that the inhibitory ability of Ponatinib on wild-type BCR-ABL1 kinase was significantly stronger than that of T315I mutant, which was consistent with the experimental inhibition activity reported in the literature. This study provided important understanding of the molecular mechanism of target proteins and inhibitors and the design of a new drug.

Key words: molecular simulation, enzyme, T315I mutant, Ponatinib, kinetic theory, reactivity

中图分类号:

Q754

陈清, 王坚毅. Ponatinib抑制野生型和T315I突变型BCR-ABL1激酶的分子模拟[J]. 化工进展, 2018, 37(02): 702-707.

CHEN Qing, WANG Jianyi. Inhibition of Ponatinib on wild-type and T315I mutant BCR-ABL1 kinase based on molecular simulation[J]. Chemical Industry and Engineering Progress, 2018, 37(02): 702-707.

参考文献

[1] GOLDMAN J M. Chronic myeloid leukemia:a historical perspective[J]. Seminars in Hematology, 2010, 47(4):302-311.
[2] COLICELLI J. ABL Tyrosine kinases:evolution of function, regulation, and specificity[J]. Science Signaling, 2010, 3(139):26.
[3] DRUKER B J. Perspectives on the development of imatinib and the future of cancer research[J]. Nature Medicine, 2009, 15(10):1149-1152.
[4] REN X, PAN X, ZHANG Z, et al. Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-abelson(Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib[J]. Journal of Medicinal Chemistry, 2013, 56(3):879-894.
[5] KIM S H, MENON H, JOOTAR S, et al. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors[J]. Haematologica, 2014, 99(7):1191-1196.
[6] 邹彬镔,石庆之.第三代BCR-ABL酪氨酸激酶抑制剂普纳替尼[J]. 中国新药与临床杂志, 2014, 33(5):329-333. ZOU B B, SHI Q Z. Third generation BCR-ABL tyrosine kinase inhibitor-ponatinib[J]. Chinese Journal of New Drugs and Clinical Remedies, 2014, 33(05):329-333.
[7] O'HARE T, SHAKESPEARE W C, ZHU X, et al. AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance[J]. Cancer Cell, 2009, 16(5):401-412.
[8] 王顺,高瑞昶.产α-淀粉酶抑制剂的药用植物内生放线菌的筛选[J]. 化工进展, 2015, 34(2):500-507, 518. WANG S, GAO R C. Screening of endophytic actinomycetes from medical plants with producing α-amylase inhibitor[J]. Chemical Industry and Engineering Progress, 2015, 34(2):500-507, 518.
[9] 韦星船,霍梦月,郑成,等.含氮姜黄素类似物的合成及其酪氨酸酶抑制效应[J]. 化工进展, 2014, 33(8):2155-2159, 2205. WEI X C, HUO M Y, ZHENG C, et al. Synthesis and tyrosinase inhibitory effect of curcumin analogues containing nitrogen[J]. Chemical Industry and Engineering Progress, 2014, 33(8):2155-2159, 2205.
[10] ZHOU T, COMMODORE L, HUANG W S, et al. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib(AP24534):lessons for overcoming kinase inhibitor resistance[J]. Chemical Biology & Drug Design, 2011, 77(1):1-11.
[11] 叶嘉炜,赵立文,张仓,等.针对T315I突变的Bcr-Abl酪氨酸激酶抑制剂研究进展[J]. 药学进展, 2014, 38(5):333-339. YE J W, ZHAO L W, ZHANG C, et al. Advances in research on Bcr-Abl tyrosine kinase inhibitors against T315I mutation[J]. Progress in Pharmaceutical Sciences, 2014, 38(5):333-339.
[12] PRONK S, PALL S, SCHULZ R, et al. GROMACS 4.5:a high-throughput and highly parallel open source molecular simulation toolkit[J]. Bioinformatics, 2013, 29(7):845-854.
[13] PIANA S, LINDORFF-LARSEN K, SHAW D E. How robust are protein folding simulations with respect to force field parameterization?[J]. Biophys. J., 2011, 100(9):47-49.
[14] SUN H Y, LI Y Y, TIAN S, et al. Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set[J]. Physical Chemistry Chemical Physics, 2014, 16(31):16719-16729.
[15] HOMEYER N, GOHLKE H. Free energy calculations by the molecular mechanics Poisson-Boltzmann surface area method[J]. Molecular Informatics, 2012, 31(2):114-122.

Ponatinib抑制野生型和T315I突变型BCR-ABL1激酶的分子模拟

Inhibition of Ponatinib on wild-type and T315I mutant BCR-ABL1 kinase based on molecular simulation

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	时永兴, 林刚, 孙晓航, 蒋韦庚, 乔大伟, 颜彬航. 二氧化碳加氢制甲醇过程中铜基催化剂活性位点研究进展[J]. 化工进展, 2023, 42(S1): 287-298.
[2]	崔守成, 徐洪波, 彭楠. 两种MOFs材料用于O₂/He吸附分离的模拟分析[J]. 化工进展, 2023, 42(S1): 382-390.
[3]	高雨飞, 鲁金凤. 非均相催化臭氧氧化作用机理研究进展[J]. 化工进展, 2023, 42(S1): 430-438.
[4]	王乐乐, 杨万荣, 姚燕, 刘涛, 何川, 刘逍, 苏胜, 孔凡海, 朱仓海, 向军. SCR脱硝催化剂掺废特性及性能影响[J]. 化工进展, 2023, 42(S1): 489-497.
[5]	赵景超, 谭明. 表面活性剂对电渗析减量化工业含盐废水的影响[J]. 化工进展, 2023, 42(S1): 529-535.
[6]	王谨航, 何勇, 史伶俐, 龙臻, 梁德青. 气体水合物阻聚剂研究进展[J]. 化工进展, 2023, 42(9): 4587-4602.
[7]	林晓鹏, 肖友华, 管奕琛, 鲁晓东, 宗文杰, 傅深渊. 离子聚合物-金属复合材料（IPMC）柔性电极的研究进展[J]. 化工进展, 2023, 42(9): 4770-4782.
[8]	李由, 吴越, 钟禹, 林琦璇, 任俊莉. 酸性熔盐水合物预处理麦秆高效制备木糖及其对酶解效率的影响[J]. 化工进展, 2023, 42(9): 4974-4983.
[9]	史天茜, 石永辉, 武新颖, 张益豪, 秦哲, 赵春霞, 路达. Fe²⁺对厌氧氨氧化EGSB反应器运行性能的影响[J]. 化工进展, 2023, 42(9): 5003-5010.
[10]	张丽宏, 金要茹, 程芳琴. 煤气化渣资源化利用[J]. 化工进展, 2023, 42(8): 4447-4457.
[11]	毛善俊, 王哲, 王勇. 基团辨识加氢：从概念到应用[J]. 化工进展, 2023, 42(8): 3917-3922.
[12]	向阳, 黄寻, 魏子栋. 电催化有机合成反应的活性和选择性调控研究进展[J]. 化工进展, 2023, 42(8): 4005-4014.
[13]	陈俊俊, 费昌恩, 段金汤, 顾雪萍, 冯连芳, 张才亮. 高生物活性聚醚醚酮化学改性研究进展[J]. 化工进展, 2023, 42(8): 4015-4028.
[14]	张耀杰, 张传祥, 孙悦, 曾会会, 贾建波, 蒋振东. 煤基石墨烯量子点在超级电容器中的应用[J]. 化工进展, 2023, 42(8): 4340-4350.
[15]	杨鹏威, 于琳竹, 王放放, 蒋昊轩, 赵光金, 李琦, 杜铭哲, 马双忱. 氨储能在新型电力系统的应用前景、挑战及发展[J]. 化工进展, 2023, 42(8): 4432-4446.